ZeroHarm Sciences raises Rs 65 Cr in Series A round

Nano formulated plant based nutraceutical brand ZeroHarm Sciences has raised Rs 65 crore ($7.15 million) in a Series A funding round. Kotak Alternate Asset Managers Limited, through its Kotak Life Sciences Fund I, invested Rs 40 crore, while Alkemi Growth Capital invested Rs 25 crore.

The funds will be used for national brand building, international expansion across the USA, the UK, and the Middle East, and scaling research and manufacturing capabilities, the company said in a press release.

Founded in 2020 by Sachin and Shweta Darbarwar, ZeroHarm Sciences develops plant based health supplements using proprietary nano formulation technology. The company aims to build India’s first Trust over Promise health platform, where supplement efficacy is demonstrated through measurable consumer health outcomes.

The Hyderabad based company converts plant based nutrients into nano sized particles to improve bioavailability and enable controlled release at lower dosages. It integrates ayurveda with advanced technology to deliver preventive wellness solutions.

ZeroHarm controls the value chain from medicinal plant sourcing through a network of over 10000 farmers in Northeast India and the Himalayas. The company has filed and received patents for nano formulations covering turmeric based phytochemicals, iron folic acid combinations, carotenoid based eye health, and synbiotic gut health compositions.

The company offers over 60 SKUs across categories such as diabetes management, heart health, joint care, immunity, gut health, oncology support, women’s wellness, and performance nutrition. Products are sold through its website, Amazon, Flipkart, and quick commerce platforms, and the brand has served more than 300000 customers.

India’s nutraceutical market is projected to reach $18 billion by 2025, while the global market is expected to cross $720 billion by 2027.

ZeroHarm competes with players including Kapiva, Plix, HealthKart, and Wellbeing Nutrition.